keyword
MENU ▼
Read by QxMD icon Read
search

GI cancer

keyword
https://www.readbyqxmd.com/read/28736844/newly-designed-silica-containing-redox-nanoparticles-for-oral-delivery-of-novel-top2-catalytic-inhibitor-for-treating-colon-cancer
#1
Long Binh Vong, Shinya Kimura, Yukio Nagasaki
Although oral drug delivery is the most common route of drug administration, the conventional polymeric nanocarriers exhibit a low drug loading capacity and low stability in the gastrointestinal (GI) environments. In this study, a newly designed silica-containing redox nanoparticle (siRNP) with reactive oxygen species (ROS) scavenging capacity is developed as an ideal oral nanocarrier for a novel hydrophobic anticancer compound BNS-22 to treat colitis-associated colon cancer in vivo. Crosslinking of silica moieties significantly enhances the stability under acidic conditions and improves BNS-22 loading capacity of siRNP compared to the conventional redox nanoparticle...
July 24, 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/28736639/promising-therapeutics-of-gastrointestinal-cancers-in-clinical-trials
#2
REVIEW
Lingling Du, Zheng Che, Andrea Wang-Gillam
Many novel therapeutics are being developed for patients with cancers along the gastrointestinal (GI) tract. These emerging agents are frequently classified by their biological targets such as tumor growth pathways, tumor metabolism, microenvironment, etc. Some agents targeting cancer growth pathways are based on existing clinically validated therapeutic targets, such as regorafenib for hepatocellular carcinoma (HCC), while other agents focus on newly identified targets, such as FGFR fusions in cholangiocarcinoma...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28736636/biological-agents-in-gastrointestinal-cancers-adverse-effects-and-their-management
#3
REVIEW
Nivedita Arora, Arjun Gupta, Preet Paul Singh
Biological therapy comprises agents that by virtue of their unique mechanisms of action, are able to specifically incite a response against or target malignant cells. They differ from conventional chemotherapy with regard to mechanisms of action, indications and side effect profile. Biologic agents have revolutionized therapy for a number of malignancies. In the setting of gastrointestinal (GI) malignancies, agents targeting vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (Her2/Neu) and epidermal growth factor receptor (EGFR) have proven to be invaluable additions to chemotherapy...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28736635/immunotherapy-in-gastrointestinal-cancers
#4
REVIEW
Patrick Grierson, Kian-Huat Lim, Manik Amin
Gastrointestinal (GI) cancers such as gastric, esophageal, pancreas, hepatobiliary, colorectal and anal cancers are a major cause of cancer related mortality worldwide. Traditional treatment options such as chemotherapy, surgery, radiation therapy, monoclonal antibodies and anti-angiogenic agents have been the backbone of treatment of GI cancers in various stages. Current cancer research is moving forward to incorporate immunotherapies in the treatment of GI cancers either as single agent or in combination with current available treatment modalities...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28736627/personalized-and-precision-medicine-integrating-genomics-into-treatment-decisions-in-gastrointestinal-malignancies
#5
REVIEW
Trang H Au, Kai Wang, David Stenehjem, Ignacio Garrido-Laguna
The advent of next generation sequencing (NGS) technologies has advanced our understanding of the intrinsic biology of different gastrointestinal (GI) tumor types. The use of novel, more efficient sequencing platforms has improved turnaround times of sequencing results. This is providing real time opportunities to put precision medicine to the test. A number of early phase clinical trials are testing targeted therapies in unique molecularly characterized subsets of patients (baskets). While basket studies are gaining momentum, treatment failures serve to remind us that shifting from a histology-driven to a histology-agnostic approach is unlikely to be a failure-free strategy for a number of tumor types as recently learnt from vemurafenib failure in BRAF mutated metastatic colorectal cancer (mCRC)...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28729021/ascend-8-a-randomized-phase-1-study-of-ceritinib-450-mg-or-600-mg-taken-with-a-low-fat-meal-versus-750-mg-in-fasted-state-in-patients-with-anaplastic-lymphoma-kinase-alk-rearranged-metastatic-non-small-cell-lung-cancer-nsclc
#6
Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, Scott A Laurie, Mark McKeage, Gloria Borra, Keunchil Park, Sang-We Kim, Marwan Ghosn, Andrea Ardizzoni, Evaristo Maiello, Alastair Greystoke, Richard Yu, Karen Osborne, Wen Gu, Jeffrey W Scott, Vanessa Q Passos, Yvonne Y Lau, Anna Wrona
INTRODUCTION: Ceritinib 750 mg fasted is approved for treatment of anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) patients previously treated with crizotinib. Part 1 of ASCEND-8 study determined whether administering ceritinib 450 mg or 600 mg with a low-fat meal may enhance gastrointestinal (GI) tolerability vs 750 mg fasted in ALK+ NSCLC patients while maintaining similar exposure. METHODS: ASCEND-8 is a multicenter, randomized, open-label, phase 1 study...
July 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28723416/unravelling-the-pharmacologic-opportunities-and-future-directions-for-targeted-therapies-in-gastro-intestinal-cancers-part-2-neuroendocrine-tumours-hepatocellular-carcinoma-and-gastro-intestinal-stromal-tumours
#7
REVIEW
Cindy Neuzillet, Louis de Mestier, Benoît Rousseau, Olivier Mir, Mohamed Hebbar, Hemant M Kocher, Philippe Ruszniewski, Christophe Tournigand
Until the 1990s, cytotoxic chemotherapy has been the cornerstone of medical therapy for gastrointestinal (GI) cancers. Better understanding of the cancer cell molecular biology has led to the therapeutic revolution of targeted therapies, i.e. monoclonal antibodies or small molecule inhibitors directed against proteins that are specifically overexpressed or mutated in cancer cells. These agents, being more specific to cancer cells, were expected to be less toxic than conventional cytotoxic agents. However, their effects have sometimes been disappointing, due to intrinsic or acquired resistance mechanisms, or to an activity restricted to some tumour settings, illustrating the importance of patient selection and early identification of predictive biomarkers of response to these therapies...
July 16, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28723307/nationwide-comprehensive-gastro-intestinal-cancer-cohorts-the-3p-initiative
#8
R R J Coebergh van den Braak, L B van Rijssen, J J van Kleef, G R Vink, M Berbee, M I van Berge Henegouwen, H J Bloemendal, M J Bruno, M C Burgmans, O R C Busch, P P L O Coene, V M H Coupé, J W T Dekker, C H J van Eijck, M A G Elferink, F L G Erdkamp, W M U van Grevenstein, J W B de Groot, N C T van Grieken, I H J T de Hingh, M C C M Hulshof, J N M Ijzermans, L Kwakkenbos, V E P P Lemmens, M Los, G A Meijer, I Q Molenaar, G A P Nieuwenhuijzen, M E de Noo, L V van de Poll-Franse, C J A Punt, R C Rietbroek, W W H Roeloffzen, T Rozema, J P Ruurda, J W van Sandick, A H W Schiphorst, H Schipper, P D Siersema, M Slingerland, D W Sommeijer, M C W Spaander, M A G Sprangers, H B A C Stockmann, M Strijker, G van Tienhoven, L M Timmermans, M L R Tjin-A-Ton, A M T van der Velden, M J Verhaar, H M Verkooijen, W J Vles, J M P G M de Vos-Geelen, J W Wilmink, D D E Zimmerman, M G H van Oijen, M Koopman, M G H Besselink, H W M van Laarhoven
BACKGROUND: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients...
July 19, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28721510/increased-genitourinary-fistula-rate-after-bevacizumab-in-recurrent-cervical-cancer-patients-initially-treated-with-definitive-radiochemotherapy-and-image-guided-adaptive-brachytherapy
#9
Alina Sturdza, Sandra Hofmann, Marlene Kranawetter, Stephan Polterauer, Christoph Grimm, Michael Krainer, Christian Kirisits, Richard Pötter, Alexander Reinthaller, Richard Schwameis
BACKGROUND AND PURPOSE: Patients with recurrent cervical cancer (RecCC) who received definitive radiochemotherapy including image-guided adaptive brachytherapy (IGABT) as primary treatment are currently treated in our institution with palliative intent by chemotherapy (CHT) combined with bevacizumab (BEV). We aim to evaluate the risk of gastrointestinal (GI)/genitourinary (GU) fistula formation in these patients. MATERIALS AND METHODS: Data of 35 consecutive patients with RecCC treated initially with radiochemotherapy and IGABT were collected...
July 18, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28717766/practice-and-impact-of-multidisciplinary-tumor-boards-on-patient-management-a-prospective-study
#10
Raghid N Charara, Firas Y Kreidieh, Rania A Farhat, Karine A Al-Feghali, Katia E Khoury, Ali Haydar, Lara Nassar, Ghina Berjawi, Ali Shamseddine, Nagi S El Saghir
PURPOSE: Multidisciplinary tumor boards (MTBs) have become commonplace. The use, attendance, and function of MTBs need continued assessment and improvement. METHODS: We prospectively recorded and assessed all cases presented at MTBs between October 2013 and December 2014. Data were collected before and during each MTB. Data were analyzed using SPSS for Windows version 23 (SPSS, Chicago, IL). RESULTS: Five hundred three cases were presented: 234 cases (46%) at GI cancer MTBs, 149 cases (29...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717701/cost-effectiveness-of-universal-hepatitis-b-virus-screening-in-patients-beginning-chemotherapy-for-sarcomas-or-gi-stromal-tumors
#11
Glorijoy Tan, Ke Zhou, Chee Hian Tan, David B Matchar, Mohamad Farid, Richard Quek, Joanne Ngeow
PURPOSE: The value of screening for hepatitis B virus (HBV) infection before chemotherapy for nonhematopoietic solid tumors remains unsettled. We evaluated the cost effectiveness of universal screening before systemic therapy for sarcomas, including GI stromal tumors (GISTs). PATIENTS AND METHODS: Drawing from the National Cancer Centre Singapore database of 1,039 patients with sarcomas, we analyzed the clinical records of 485 patients who received systemic therapy...
August 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717373/diagnostic-value-of-alarm-symptoms-for-upper-gi-malignancy-in-patients-referred-to-gi-clinic-a-7-years-cross-sectional-study
#12
Mohammad Hasan Emami, Masoud Ataie-Khorasgani, Nasim Jafari-Pozve
BACKGROUND: Early upper gastrointestinal (UGI) cancer detection had led to organ-preserving endoscopic therapy. Endoscopy is a suitable method of early diagnosis of UGI malignancies. In Iran, exclusion of malignancy is the most important indication for endoscopy. This study is designed to see whether using alarm symptoms can predict the risk of cancer in patients. MATERIALS AND METHODS: A total of 3414 patients referred to a tertiary gastrointestinal (GI) clinic in Isfahan, Iran, from 2009 to 2016 with dyspepsia, gastroesophageal reflux disease (GERD), and alarm symptoms, such as weight loss, dysphagia, GI bleeding, vomiting, positive familial history for cancer, and anorexia...
2017: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://www.readbyqxmd.com/read/28711479/identification-of-the-suitable-leaf-margin-for-liver-stereotactic-body-radiotherapy-with-flattening-filter-free-beams
#13
Toshiyuki Ogata, Hideki Nishimura, Hiroshi Mayahara, Kazuyuki Uehara, Takanobu Okayama
The purpose of this study is to identify the suitable leaf margin for liver stereotactic body radiotherapy (SBRT) with flattening filter-free (FFF) beams, as compared with that with flattening filter (FF) beams. SBRT treatment planning for 10 patients with liver cancer was performed using 10-MV FFF and FF beams obtained from a Varian TrueBeam (Varian Medical Systems, Palo Alto, CA) linear accelerator. Each plan was generated with the leaf margin to the planning target volume (PTV) ranging from -3 to 5 mm...
July 12, 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/28710508/risk-of-gastrointestinal-events-with-newly-approved-after-2011-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitors-in-cancer-patients-a-meta-analysis-of-randomized-controlled-trials
#14
REVIEW
Jing Li, Jian Gu
PURPOSE: We performed a meta-analysis to systematically review the gastrointestinal (GI) events (diarrhea, nausea, vomiting, anorexia) of five newly approved (after 2011) VEGFR-TKIs in cancer patients. METHODS: The relevant studies of the randomized controlled trials (RCTs) in cancer patients treated with cabozantinib, vandetanib, lenvatinib, regorafenib, and axitinib were retrieved and the systematic evaluation was conducted. RESULTS: Forty-one randomized controlled trials and 10,860 patients were included...
July 15, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28707966/targeted-molecular-ablation-of-cancer-stem-cells-for-curing-gastrointestinal-cancers
#15
Yong Seok Kim, Ho Jae Lee, Jong-Min Park, Young-Min Han, Napapan Kangwan, Ji Young Oh, Dong Yoon Lee, Ki Baik Hahm
Abundance of the ATPase-binding cassette (ABC) transporters and deranged self-renewal pathways characterize the presence of cancer stem cells (CSCs) in gastrointestinal cancers (GI cancers), which play crucial roles in tumorigenesis, chemotherapy resistance, tumor recurrence, and cancer metastasis. Therefore, in order to ensure high cure rates, chemoquiescence, CSCs should be ablated. Recent advances in either understanding CSCs or biomarker identification enable scientists to develop techniques for ablating CSCs and clinicians to provide cancer cure, especially in GI cancers characterized by inflammation-driven carcinogenesis...
July 14, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28706889/long-term-oncologic-outcomes-of-laparoscopic-surgery-for-splenic-flexure-colon-cancer-are-comparable-to-conventional-open-surgery
#16
Min Ki Kim, In Kyu Lee, Won-Kyung Kang, Hyeon-Min Cho, Bong-Hyeon Kye, Heba Essam Jalloun, Jun-Gi Kim
PURPOSE: Few studies about laparoscopic surgery for splenic flexure colon cancer have been published. This study aims to compare the short- and long-term outcomes of laparoscopic surgery for splenic flexure colon cancer with those of conventional open surgery. METHODS: From January 2004 to December 2010, 51 consecutive patients who underwent curative resection for stages I-III splenic flexure colon cancer were enrolled. Thirty-three patients underwent laparoscopy-assisted colectomy, while 18 patients underwent conventional open colectomy...
July 2017: Annals of Surgical Treatment and Research
https://www.readbyqxmd.com/read/28704159/one-does-not-fit-all-health-audience-segmentation-and-prediction-of-health-behaviors-in-cancer-prevention
#17
Myoung-Gi Chon, Hyojung Park
The purpose of this study is to propose a health belief model-based approach to segmenting health audiences in order to improve targeting of cancer prevention efforts. This study also examines how the identified health segments differ in cancer prevention behaviors. Using data from the 2013 Health Information National Trends Survey, a cluster analysis resulted in three distinct health audience groups: (a) health aware, (b) health at risk, and (c) health in confidence. MANOVA tests indicate that these segments differ significantly regarding healthy diet and exercise...
July 13, 2017: Health Marketing Quarterly
https://www.readbyqxmd.com/read/28701864/induction-of-forkhead-class-box-o3a-and-apoptosis-by-a-standardized-ginsenoside-formulation-kg-135-is-potentiated-by-autophagy-blockade-in-a549-human-lung-cancer-cells
#18
Chih-Jung Yao, Jyh-Ming Chow, Shuang-En Chuang, Chia-Lun Chang, Ming-De Yan, Hsin-Lun Lee, I-Chun Lai, Pei-Chun Lin, Gi-Ming Lai
BACKGROUND: KG-135, a standardized formulation enriched with Rk1, Rg3, and Rg5 ginsenosides, has been shown to inhibit various types of cancer cells; however, the underlying mechanisms are not fully understood. In this study, we explored its effects in A549 human lung cancer cells to investigate the induction of Forkhead Class box O3a (FOXO3a) and autophagy. METHODS: Cell viability was determined by sulforhodamine B staining. Apoptosis and cell cycle distribution were analyzed using flow cytometry...
July 2017: Journal of Ginseng Research
https://www.readbyqxmd.com/read/28699351/ultrahypofractionated-cyberknifetm-based-stereotactic-radiotherapy-versus-conventional-radiotherapy-in-patients-with-prostate-cancer-acute-toxicity-evaluation-in-two-phase-ii-prospective-studies
#19
G Głowacki, W Majewski, P Wojcieszek, K Grabinska, G Wozniak, L Miszczyk
Our purpose was to compare the acute toxicity of ultrahypofractionated CyberKnifeTM based stereotactic radiotherapy (SBRT Arm) and conventional radiotherapy (EBRT Arm) in prostate cancer patients. Two-hundred-sixteen men with prostate cancer were enrolled in our prospective studies. One-hundred and nine were irradiated using CyberKnife to total dose of 36,25 Gy in 5 fractions. One-hundred and seven were irradiated conventionally to total dose of 76 Gy in 38 fractions. Mean age of patients was 69. Acute genitourinary (GU) and gastrointestinal (GI) adverse-events were collected...
2017: Neoplasma
https://www.readbyqxmd.com/read/28697317/management-of-malignant-bowel-obstruction-associated-with-gi-cancers
#20
Aaron J Franke, Atif Iqbal, Jason S Starr, Rajesh M Nair, Thomas J George
For many patients with GI malignancies, the seeding of the abdominal cavity with tumor cells, called peritoneal carcinomatosis, is a common mode of metastases and disease progression. Prognosis for patients with this aspect of their disease remains poor, with high disease-related morbidity and complications. Uniform and proven practices that provide optimal palliative care and quality of life for these patients are needed. The objective of this review is to critically assess the current literature regarding palliative strategies in the management of peritoneal carcinomatosis and associated symptoms in patients with advanced GI cancers...
July 2017: Journal of Oncology Practice
keyword
keyword
30509
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"